Early Infliximab Yields Superior Long-Term Effects on Linear Growth in Pediatric Crohn's Disease Patients
Gut and Liver
;
: 255-262, 2018.
Article
Dans Anglais
| WPRIM
| ID: wpr-714616
ABSTRACT
BACKGROUND/AIMS:
Information regarding the efficacy of early infliximab treatment in pediatric patients with Crohn's disease (CD) is limited. We aimed to evaluate the impact of early combined immunosuppression on linear growth in pediatric patients with CD by performing step-up comparisons.METHODS:
This retrospective study included pediatric patients with moderate-to-severe CD, who received a combination therapy with infliximab and azathioprine for at least 3 years and sustained corticosteroid-free remission without loss of response. The z-scores of the growth indicators obtained at the time of diagnosis and annually for 3 years thereafter were compared between the two groups.RESULTS:
The early combined immunosuppression group displayed significantly increased linear growth 3 years after diagnosis (p=0.026). A significant difference was also observed in the linear growth 3 years after diagnosis between subgroups of Tanner stages 1–2 (p=0.016).CONCLUSIONS:
The early introduction of biologics should be considered to improve linear growth in pediatric patients with CD.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Azathioprine
/
Produits biologiques
/
Maladie de Crohn
/
Études rétrospectives
/
Immunosuppression thérapeutique
/
Diagnostic
/
Infliximab
Type d'étude:
Etude diagnostique
/
Étude observationnelle
Limites du sujet:
Humains
langue:
Anglais
Texte intégral:
Gut and Liver
Année:
2018
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS